Regeneron has posted findings from a large trial of its COVID-19 antibody cocktail showing the therapy reduced risk of hospitalisation or death by 70%.
At the start of the pandemic GlaxoSmithKline made its vaccine booster tech available looking for collaborations with other vaccine developers – but GSK has been lagging behind rivals like P
